About Navignostics
Navignostics is dedicated to fighting cancer by enabling personalized treatments.
We analyze tumor samples to determine the best way to target each cancerous growth, helping clinicians find the right therapy for each patient and supporting researchers in developing new drugs.
Founded in 2022 as a spin-off from the University of Zurich Bodenmiller Lab, Navignostics operates from its laboratory and headquarters in Horgen, Switzerland. The team consists of scientists, lab technicians, software developers, and business experts working together to solve complex problems in cancer treatment and research.
Technology and Research
Navignostics combines highly multiplex protein imaging with advanced data analytics for spatial single-cell proteomics, validated by over a decade of translational and clinical research.
The company supports translational research and biomarker identification to aid drug developers in selecting the right patient groups for clinical trials, enhancing the success of novel treatment approaches.
Our Mission
The mission of Navignostics is to leverage clinicians' patient expertise and researchers' discoveries with innovative technologies to create a future where cancer no longer threatens quality of life.